Abstract
Objective To assess regional variation in the use of late preterm steroids use after the publication of the Antenatal Late Preterm Steroids (ALPS) Trial and to understand factors associated with a region’s pace of adoption.
Methods This was a repeated cross-sectional study using US natality data across hospital referral regions (HRRs) within the US from February 2015 to October 2017. Inclusion criteria included live-born, non-anomalous, singleton, late preterm (34-36 completed weeks of gestation) neonates born to individuals without pregestational diabetes. HRRs were categorized as either a “slower” or “faster” adopter of antenatal late preterm steroids based on the observed versus expected pace of antenatal steroid adoption in a 1-year period after the trial’s dissemination compared to a 1-year pre-dissemination period. Patient and regional factors hypothesized a priori to be associated with the uptake of late preterm steroids were compared between faster and slower adopters.
Results There were 666,097 late preterm births in 282 HRRs during the study period. Of the included HRRs, 136 (48.2%) were considered faster adopters and 146 (51.8%) slower adopters. Faster adopters increased their steroid use by 12.1-percentage points (5.9% to 18.0%) compared to a 5.5-point increase (3.7% to 9.2%) among slower adopters (p<0.001). Most examined patient and regional factors were not associated with a region’s pace of adoption. The only factor associated with being a faster adopter was the regional prevalence of prior preterm birth (adjusted odds ratio 2.04, 95% confidence interval 1.48-2.82).
Conclusion There was widespread geographic variation in the adoption of antenatal steroid administration for late preterm births that largely remained unexplained by population factors. Future research should focus on patient, provider, and system-level factors that may be influencing the adoption of late preterm steroids. Namely, this work can provide insights to barriers to timely or equitable access to new evidence-based practices and can guide future dissemination strategies with the goal of more uniform adoption.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: Dr. Clapp reports grants from the Society for Maternal-Fetal Medicine and the Risk Management Foundation of the Harvard Medical Institutions, Inc., and serves as a medical advisory board member with private equity in Delfina Health, outside the submitted work. Dr. Melamed reports grants from the National Center for Advancing Translational Sciences, the National Cancer Institute, and the Conquer Cancer-The ASCO Foundation, and the Department of Defense outside the submitted work. Dr. Melamed has also served as an advisor for AstraZeneca. Dr. Wright has received research funding from Merck and honoraria from UpToDate.
Conflicts of interest: The authors declare no conflicts of interest or financial support for this project.
Data Availability
Data used to construct this analysis can be found at: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm
